Viatris Inc. (VTRS)
USD 7.63
(1.19%)
USD 7.63
(1.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 27.21 Billion USD | -5.98% |
| 2022 | 28.94 Billion USD | -15.72% |
| 2021 | 34.35 Billion USD | -11.01% |
| 2020 | 38.59 Billion USD | 99.25% |
| 2019 | 19.37 Billion USD | -5.82% |
| 2018 | 20.56 Billion USD | -8.58% |
| 2017 | 22.49 Billion USD | -4.7% |
| 2016 | 23.6 Billion USD | 88.84% |
| 2015 | 12.5 Billion USD | -0.34% |
| 2014 | 12.54 Billion USD | 1.7% |
| 2013 | 12.33 Billion USD | 43.83% |
| 2012 | 8.57 Billion USD | 5.96% |
| 2011 | 8.09 Billion USD | 2.17% |
| 2010 | 7.92 Billion USD | 3.46% |
| 2009 | 7.65 Billion USD | 0.66% |
| 2008 | 7.6 Billion USD | -3.9% |
| 2007 | 7.91 Billion USD | 0.0% |
| 2006 | 1.08 Billion USD | 273.74% |
| 2005 | 1.08 Billion USD | 273.74% |
| 2004 | 289.73 Million USD | 34.45% |
| 2003 | 215.5 Million USD | 0.0% |
| 2002 | 214.47 Million USD | -35.68% |
| 2001 | 333.43 Million USD | 142.49% |
| 2000 | 137.5 Million USD | -6.33% |
| 1999 | 146.8 Million USD | 42.11% |
| 1998 | 103.3 Million USD | -12.38% |
| 1997 | 117.9 Million USD | 55.95% |
| 1996 | 75.6 Million USD | 19.06% |
| 1995 | 63.5 Million USD | 172.53% |
| 1994 | 23.3 Million USD | -57.71% |
| 1993 | 55.1 Million USD | 137.5% |
| 1992 | 23.2 Million USD | 42.33% |
| 1991 | 16.3 Million USD | 58.25% |
| 1990 | 10.3 Million USD | 22.62% |
| 1989 | 8.4 Million USD | -56.02% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 25.81 Billion USD | -5.56% |
| 2024 Q1 | 27.32 Billion USD | 0.41% |
| 2023 FY | 27.21 Billion USD | -5.98% |
| 2023 Q4 | 27.21 Billion USD | -2.36% |
| 2023 Q3 | 27.87 Billion USD | 0.09% |
| 2023 Q1 | 28.36 Billion USD | -2.03% |
| 2023 Q2 | 27.85 Billion USD | -1.8% |
| 2022 Q4 | 28.94 Billion USD | -1.8% |
| 2022 FY | 28.94 Billion USD | -15.72% |
| 2022 Q1 | 33.01 Billion USD | -3.87% |
| 2022 Q2 | 31.31 Billion USD | -5.15% |
| 2022 Q3 | 29.48 Billion USD | -5.87% |
| 2021 Q2 | 36.77 Billion USD | -2.1% |
| 2021 Q3 | 34.92 Billion USD | -5.03% |
| 2021 Q4 | 34.35 Billion USD | -1.66% |
| 2021 FY | 34.35 Billion USD | -11.01% |
| 2021 Q1 | 37.56 Billion USD | -2.68% |
| 2020 Q1 | 18.88 Billion USD | -2.52% |
| 2020 Q2 | 18.4 Billion USD | -2.51% |
| 2020 Q3 | 18.69 Billion USD | 1.55% |
| 2020 Q4 | 38.59 Billion USD | 106.46% |
| 2020 FY | 38.59 Billion USD | 99.25% |
| 2019 Q3 | 19.59 Billion USD | -1.63% |
| 2019 Q4 | 19.37 Billion USD | -1.11% |
| 2019 Q1 | 20.01 Billion USD | -2.69% |
| 2019 FY | 19.37 Billion USD | -5.82% |
| 2019 Q2 | 19.91 Billion USD | -0.5% |
| 2018 Q2 | 21.06 Billion USD | -4.29% |
| 2018 FY | 20.56 Billion USD | -8.58% |
| 2018 Q4 | 20.56 Billion USD | -3.84% |
| 2018 Q3 | 21.38 Billion USD | 1.55% |
| 2018 Q1 | 22 Billion USD | -2.18% |
| 2017 Q3 | 22.52 Billion USD | -0.64% |
| 2017 FY | 22.49 Billion USD | -4.7% |
| 2017 Q4 | 22.49 Billion USD | -0.13% |
| 2017 Q2 | 22.67 Billion USD | 0.25% |
| 2017 Q1 | 22.61 Billion USD | -4.2% |
| 2016 Q4 | 23.6 Billion USD | -4.46% |
| 2016 Q2 | 18.5 Billion USD | 49.61% |
| 2016 Q3 | 24.7 Billion USD | 33.53% |
| 2016 FY | 23.6 Billion USD | 88.84% |
| 2016 Q1 | 12.36 Billion USD | -1.06% |
| 2015 Q3 | 11.5 Billion USD | -13.03% |
| 2015 Q1 | 13.03 Billion USD | 3.88% |
| 2015 Q2 | 13.22 Billion USD | 1.49% |
| 2015 Q4 | 12.5 Billion USD | 8.7% |
| 2015 FY | 12.5 Billion USD | -0.86% |
| 2014 Q2 | 12.25 Billion USD | 0.71% |
| 2014 Q4 | 12.54 Billion USD | 6.6% |
| 2014 Q1 | 12.16 Billion USD | -1.39% |
| 2014 Q3 | 11.76 Billion USD | -3.94% |
| 2014 FY | 12.61 Billion USD | 2.72% |
| 2013 FY | 12.27 Billion USD | 43.15% |
| 2013 Q1 | 8.99 Billion USD | 4.92% |
| 2013 Q2 | 9.26 Billion USD | 2.98% |
| 2013 Q4 | 12.33 Billion USD | 27.57% |
| 2013 Q3 | 9.66 Billion USD | 0.0% |
| 2012 FY | 8.57 Billion USD | 5.96% |
| 2012 Q2 | 8.4 Billion USD | 3.04% |
| 2012 Q1 | 8.15 Billion USD | 0.76% |
| 2012 Q3 | 8.08 Billion USD | -3.82% |
| 2012 Q4 | 8.57 Billion USD | 6.11% |
| 2011 Q3 | 7.62 Billion USD | -6.16% |
| 2011 Q1 | 7.96 Billion USD | 0.5% |
| 2011 FY | 8.09 Billion USD | 2.17% |
| 2011 Q4 | 8.09 Billion USD | 6.16% |
| 2011 Q2 | 8.12 Billion USD | 2.06% |
| 2010 Q4 | 7.92 Billion USD | 0.73% |
| 2010 FY | 7.92 Billion USD | 3.46% |
| 2010 Q3 | 7.86 Billion USD | 3.22% |
| 2010 Q2 | 7.61 Billion USD | -0.33% |
| 2010 Q1 | 7.64 Billion USD | -0.16% |
| 2009 Q2 | 7.33 Billion USD | 1.14% |
| 2009 Q1 | 7.24 Billion USD | -5.6% |
| 2009 FY | 7.65 Billion USD | -0.27% |
| 2009 Q4 | 7.65 Billion USD | -0.44% |
| 2009 Q3 | 7.69 Billion USD | 4.91% |
| 2008 Q4 | 7.67 Billion USD | -4.22% |
| 2008 Q2 | 8.34 Billion USD | -0.82% |
| 2008 Q1 | 8.41 Billion USD | 0.0% |
| 2008 FY | 7.67 Billion USD | -3.01% |
| 2008 Q3 | 8.01 Billion USD | -3.91% |
| 2007 Q2 | 2.71 Billion USD | 5.94% |
| 2007 FY | 7.91 Billion USD | 630.96% |
| 2007 Q1 | 2.56 Billion USD | 131.89% |
| 2007 Q3 | 2.55 Billion USD | -5.84% |
| 2006 Q1 | 1.08 Billion USD | 0.67% |
| 2006 Q2 | 1.11 Billion USD | 2.85% |
| 2006 Q3 | 1.07 Billion USD | -3.13% |
| 2006 Q4 | 1.1 Billion USD | 2.4% |
| 2006 FY | 1.08 Billion USD | 273.74% |
| 2005 Q1 | 289.73 Million USD | 35.66% |
| 2005 FY | 289.73 Million USD | 34.45% |
| 2005 Q2 | 306.9 Million USD | 5.93% |
| 2005 Q3 | 1.08 Billion USD | 253.01% |
| 2005 Q4 | 1.07 Billion USD | -0.72% |
| 2004 Q1 | 215.5 Million USD | -25.84% |
| 2004 Q4 | 213.56 Million USD | 1.91% |
| 2004 Q3 | 209.57 Million USD | -25.51% |
| 2004 FY | 215.5 Million USD | -27.9% |
| 2004 Q2 | 281.32 Million USD | 30.55% |
| 2003 Q4 | 290.58 Million USD | 8.81% |
| 2003 Q2 | 226.88 Million USD | -24.09% |
| 2003 Q1 | 298.89 Million USD | -1.0% |
| 2003 FY | 298.89 Million USD | 39.36% |
| 2003 Q3 | 267.04 Million USD | 17.7% |
| 2002 Q4 | 301.92 Million USD | 25.87% |
| 2002 Q3 | 239.86 Million USD | 13.73% |
| 2002 Q2 | 210.91 Million USD | -1.66% |
| 2002 FY | 214.47 Million USD | -35.68% |
| 2002 Q1 | 214.47 Million USD | -47.66% |
| 2001 Q2 | 350.68 Million USD | 5.17% |
| 2001 FY | 333.43 Million USD | 142.49% |
| 2001 Q4 | 409.79 Million USD | 2.12% |
| 2001 Q3 | 401.29 Million USD | 14.43% |
| 2001 Q1 | 333.43 Million USD | 10.51% |
| 2000 Q1 | 137.5 Million USD | -9.0% |
| 2000 Q3 | 271.7 Million USD | -18.58% |
| 2000 FY | 137.5 Million USD | -6.33% |
| 2000 Q4 | 301.71 Million USD | 11.05% |
| 2000 Q2 | 333.69 Million USD | 142.67% |
| 1999 Q1 | 146.8 Million USD | 9.31% |
| 1999 Q2 | 153 Million USD | 4.22% |
| 1999 Q3 | 138.7 Million USD | -9.35% |
| 1999 FY | 146.8 Million USD | 42.11% |
| 1999 Q4 | 151.1 Million USD | 8.94% |
| 1998 Q2 | 116.2 Million USD | 12.49% |
| 1998 Q1 | 103.3 Million USD | 4.55% |
| 1998 Q3 | 117.1 Million USD | 0.77% |
| 1998 Q4 | 134.3 Million USD | 14.69% |
| 1998 FY | 103.3 Million USD | -12.38% |
| 1997 Q3 | 116.3 Million USD | 1.22% |
| 1997 Q4 | 98.8 Million USD | -15.05% |
| 1997 Q1 | 117.9 Million USD | -9.03% |
| 1997 FY | 117.9 Million USD | 55.95% |
| 1997 Q2 | 114.9 Million USD | -2.54% |
| 1996 Q1 | 75.6 Million USD | 34.52% |
| 1996 Q4 | 129.6 Million USD | 1.97% |
| 1996 Q3 | 127.1 Million USD | 47.45% |
| 1996 Q2 | 86.2 Million USD | 14.02% |
| 1996 FY | 75.6 Million USD | 19.06% |
| 1995 FY | 63.5 Million USD | 172.53% |
| 1995 Q2 | 59 Million USD | -7.09% |
| 1995 Q1 | 63.5 Million USD | 9.29% |
| 1995 Q4 | 56.2 Million USD | 16.6% |
| 1995 Q3 | 48.2 Million USD | -18.31% |
| 1994 Q3 | 46.6 Million USD | 7.62% |
| 1994 Q1 | 23.3 Million USD | -18.25% |
| 1994 Q2 | 43.3 Million USD | 85.84% |
| 1994 Q4 | 58.1 Million USD | 24.68% |
| 1994 FY | 23.3 Million USD | -57.71% |
| 1993 Q1 | 55.1 Million USD | 92.66% |
| 1993 Q3 | 26.4 Million USD | -25.63% |
| 1993 FY | 55.1 Million USD | 137.5% |
| 1993 Q2 | 35.5 Million USD | -35.57% |
| 1993 Q4 | 28.5 Million USD | 7.95% |
| 1992 Q1 | 23.2 Million USD | 4.98% |
| 1992 Q3 | 30.5 Million USD | 15.53% |
| 1992 Q2 | 26.4 Million USD | 13.79% |
| 1992 Q4 | 28.6 Million USD | -6.23% |
| 1992 FY | 23.2 Million USD | 42.33% |
| 1991 Q4 | 22.1 Million USD | 12.76% |
| 1991 Q3 | 19.6 Million USD | 7.1% |
| 1991 FY | 16.3 Million USD | 58.25% |
| 1991 Q2 | 18.3 Million USD | 12.27% |
| 1991 Q1 | 16.3 Million USD | -7.39% |
| 1990 Q2 | 15.4 Million USD | 49.51% |
| 1990 Q3 | 17.9 Million USD | 16.23% |
| 1990 Q4 | 17.6 Million USD | -1.68% |
| 1990 FY | 10.3 Million USD | 22.62% |
| 1990 Q1 | 10.3 Million USD | -45.21% |
| 1989 Q1 | 8.4 Million USD | 0.0% |
| 1989 Q4 | 18.8 Million USD | 59.32% |
| 1989 Q3 | 11.8 Million USD | -9.23% |
| 1989 Q2 | 13 Million USD | 54.76% |
| 1989 FY | 8.4 Million USD | -56.02% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | -2771.48% |
| Embecta Corp. | 2.03 Billion USD | -1236.776% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -5670.544% |
| Dynavax Technologies Corporation | 375.02 Million USD | -7157.696% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -4019.024% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -3764.802% |
| PainReform Ltd. | 2.69 Million USD | -1011349.275% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -16506.022% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -443220.412% |
| SCYNEXIS, Inc. | 55.45 Million USD | -48985.843% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -295857.935% |
| Cosmos Health Inc. | 30.25 Million USD | -89869.68% |
| Journey Medical Corporation | 56.49 Million USD | -48074.481% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -443220.412% |
| Safety Shot Inc | 3.89 Million USD | -699226.626% |
| Alpha Teknova, Inc. | 38.55 Million USD | -70502.838% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -19785.951% |
| Bright Green Corporation | 6.43 Million USD | -422665.902% |
| Procaps Group, S.A. | 462.06 Million USD | -5790.535% |
| Theratechnologies Inc. | 98.63 Million USD | -27493.65% |
| Harrow Health, Inc. | 241.75 Million USD | -11158.64% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -310750.845% |
| Biofrontera Inc. | 23.13 Million USD | -117528.679% |
| DURECT Corporation | 30.4 Million USD | -89415.556% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -5483.647% |
| Cronos Group Inc. | 43.73 Million USD | -62132.598% |
| OptiNose, Inc. | 194.33 Million USD | -13905.763% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | -3229.969% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -56083.507% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -129645.157% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -14907.609% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -721457.081% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -51728.001% |
| Radius Health, Inc. | 804.29 Million USD | -3284.115% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -197787.487% |
| ProPhase Labs, Inc. | 42.54 Million USD | -63876.354% |
| Phibro Animal Health Corporation | 725.54 Million USD | -3651.411% |
| Procaps Group S.A. | 462.06 Million USD | -5790.535% |
| Alvotech | 1.88 Billion USD | -1345.785% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -194009.97% |
| Rockwell Medical, Inc. | 30.88 Million USD | -88035.807% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -30015.514% |
| SIGA Technologies, Inc. | 57.97 Million USD | -46846.144% |
| Tilray Brands, Inc. | 892.11 Million USD | -2950.956% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -12283.121% |
| Shineco, Inc. | 47.6 Million USD | -57078.859% |
| PetIQ, Inc. | 645.22 Million USD | -4118.369% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -12399267.688% |
| Incannex Healthcare Limited | 5.83 Million USD | -466762.779% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -2570.012% |
| Alimera Sciences, Inc. | 107.35 Million USD | -25253.597% |
| Silver Spike Investment Corp. | 3 Million USD | -904206.587% |
| Assertio Holdings, Inc. | 148.41 Million USD | -18239.06% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -1435480.298% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -127589.957% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -387291.119% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -320470.056% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -15597.89% |
| Hempacco Co., Inc. | 18.82 Million USD | -144504.794% |
| Talphera, Inc. | 6.29 Million USD | -432620.191% |
| Alvotech | 1.88 Billion USD | -1345.785% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -15669.467% |
| Lantheus Holdings, Inc. | 835.25 Million USD | -3158.65% |
| Currenc Group, Inc. | 177.67 Million USD | -15218.975% |
| Kamada Ltd. | 109.96 Million USD | -24650.862% |
| Indivior PLC | 1.95 Billion USD | -1294.912% |
| Evoke Pharma, Inc. | 9.64 Million USD | -282008.891% |
| Flora Growth Corp. | 17.22 Million USD | -157942.62% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -320470.056% |
| Evolus, Inc. | 209.68 Million USD | -12880.347% |
| HUTCHMED (China) Limited | 536.38 Million USD | -4974.349% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | -3016.014% |
| Akanda Corp. | 12.66 Million USD | -214742.111% |